ReviewEuropean journal of pediatrics2017
The ethical framework for performing research with rare inherited neurometabolic disease patients.
Review in European journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Generative AI-Assisted Medical Illustrations in Pediatric Neurosurgery : Workflows, Ethical Safeguards, and Journal Policy Considerations.Journal of Korean Neurosurgical Society · 2026Review
- Glycogen and Glycosylation: Friends or Foes?Biomolecules · 2026Review
- Ethics and regulatory guidance to address the challenges encountered in research on rare diseases in a multinational dimension: the experience of a European funded programme.BMC medical ethics · 2026Article
- Engaging children, adolescents and young adults living with rare diseases as research partners: practical considerations for meaningful involvement.Frontiers in pediatrics · 2026Article
- Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis.Orphanet journal of rare diseases · 2023Article
- PedCRIN tool for the biosamples management in pediatric clinical trials.Clinical and translational science · 2023Article
- Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review.Frontiers in medicine · 2022Article
- Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project.BMC medical ethics · 2021Article
- Genetic Testing in Natural History Studies: A Review of the Regulatory and Legal Landscape.Public health genomics · 2021Review
- Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- CDG Therapies: From Bench to Bedside.International journal of molecular sciences · 2018Review
- Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for performing clinical trials to develop well-studied and appropriate medicines for inherited neurometabolic disease patients faces ethical concerns mainly raising from four aspects: the diseases are rare; include young and very young patients; the neurological impairment may compromise the capability to provide 'consent'; and the genetic nature of the disease leads to further ethical implications. This work is intended to identify the ethical provisions applicable to clinical research involving these patients and to evaluate if these cover the ethical issues. Three searches have been performed on the European regulatory/legal framework, the literature and European Union-funded projects. The European legal framework offers a number of ethical provisions ruling the clinical research on paediatric, rare, inherited diseases with neurological symptoms. In the literature, relevant publications deal with informed consent, newborn genetic screenings, gene therapy and rights/interests of research participants. Additional information raised from European projects on sharing patients' data from different countries, the need to fill the gap of the regulatory framework and to improve information to stakeholders and patients/families.
conclusionSeveral recommendations and guidelines on ethical aspects are applicable to the inherited neurometabolic disease research in Europe, even though they suffer from the lack of a common ethical approach. What is Known: • When planning and conducting clinical trials, sponsors and researchers know that clinical trials are to be performed according to well-established ethical rules, and patients should be aware about their rights. • In the cases of paediatric patients, vulnerable patients unable to provide consent, genetic diseases' further rules apply. What is New: • This work discusses which ethical rules apply to ensure protection of patient's rights if all the above-mentioned features coexist. • This work shows available data and information on how these rules have been applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.